Olmesartan/Hidroclorotiazida Viatris shortage — ES supply status & alternatives

Olmesartan/Hidroclorotiazida Viatris

—

In supply · Australia

In supply · 🇦🇺 Australia · short in🇪🇸 ES

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Controlled substance
Active ingredient (INN)	Olmesartan/Hidroclorotiazida Viatris
Therapeutic category	Auto-created by Agencia Española de Medicamentos — Problemas de Suministro scraper

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 4 resolved events

◷

0–9 months

Historical pattern from resolved shortage records — not a prediction of this event.

Shortage status by regulator official notices

🇪🇸

Spain

AEMPS · 1d ago

Medium

Verified timeline regulator events

🇪🇸 3 May 2026

medium reported

🇪🇸 6 Apr 2026

Shortage resolved

🇪🇸 23 Oct 2025

medium reported

🇪🇸 18 Aug 2025

Shortage resolved

🇪🇸 16 July 2025

Shortage resolved

🇪🇸 19 Jan 2025

Shortage resolved

Sources official regulators

🇪🇸

AEMPS

verified 1d ago

verify ↗

Mederti Drug Report

Generated 5 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.